company background image
2633

Jacobson PharmaSEHK:2633 Stock Report

Market Cap

HK$1.1b

7D

-3.2%

1Y

-49.2%

Updated

15 Oct, 2021

Data

Company Financials
2633 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance1/6
Financial Health4/6
Dividends2/6

2633 Overview

Jacobson Pharma Corporation Limited, through its subsidiaries, manufactures, markets, and sells generic drugs and branded healthcare products in Hong Kong, China, Macau, Singapore, and internationally.

Price History & Performance

Summary of all time highs, changes and price drops for Jacobson Pharma
Historical stock prices
Current Share PriceHK$0.60
52 Week HighHK$0.58
52 Week LowHK$1.40
Beta0.32
1 Month Change-10.45%
3 Month Change-14.29%
1 Year Change-49.15%
3 Year Change-62.50%
5 Year Change-59.73%
Change since IPO-64.29%

Recent News & Updates

Sep 24
Jacobson Pharma (HKG:2633) Is Reducing Its Dividend To HK$0.015

Jacobson Pharma (HKG:2633) Is Reducing Its Dividend To HK$0.015

Jacobson Pharma Corporation Limited ( HKG:2633 ) has announced it will be reducing its dividend payable on the 19th of...

Sep 16
Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year

Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year

Shareholders will probably not be too impressed with the underwhelming results at Jacobson Pharma Corporation Limited...

Feb 03
Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares

Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares

Whilst it may not be a huge deal, we thought it was good to see that the Jacobson Pharma Corporation Limited ( HKG:2633...

Shareholder Returns

2633HK PharmaceuticalsHK Market
7D-3.2%0.5%1.1%
1Y-49.2%-14.9%5.3%

Return vs Industry: 2633 underperformed the Hong Kong Pharmaceuticals industry which returned -16% over the past year.

Return vs Market: 2633 underperformed the Hong Kong Market which returned 5% over the past year.

Price Volatility

Is 2633's price volatile compared to industry and market?
2633 volatility
2633 Beta0.32
Industry Beta0.60
Market Beta1

Stable Share Price: 2633 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: 2633's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20161,695Derek Sumhttps://www.jacobsonpharma.com

Jacobson Pharma Corporation Limited, through its subsidiaries, manufactures, markets, and sells generic drugs and branded healthcare products in Hong Kong, China, Macau, Singapore, and internationally. The company offers generic drugs for various therapeutic categories, including respiratory, cardiovascular, central nervous system, gastrointestinal, scar treatment, oral anti-diabetics, anti-infective, arsenic trioxide oral solution, dihydrocodeine tablet, perindopril tablet, atomoxetine capsule, rosuvastatin tablet, hydroxychloroquine tablet, desloratadine tablet, metronidazole gel, and ofloxacin eye drops. It also provides branded medicines; health and wellness products; and proprietary Chinese medicines, such as Po Chai pills, Ho Chai Kung Tji Thung San, Tong Tai Chung Woodlok oil, Flying Eagle Woodlok Oil, Saplingtan, Shiling oil, Contractubex, Doan's Ointment, and Col-gan tablet.

Jacobson Pharma Fundamentals Summary

How do Jacobson Pharma's earnings and revenue compare to its market cap?
2633 fundamental statistics
Market CapHK$1.15b
Earnings (TTM)HK$173.71m
Revenue (TTM)HK$1.45b

6.6x

P/E Ratio

0.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
2633 income statement (TTM)
RevenueHK$1.45b
Cost of RevenueHK$884.83m
Gross ProfitHK$561.08m
ExpensesHK$387.37m
EarningsHK$173.71m

Last Reported Earnings

Mar 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.091
Gross Margin38.80%
Net Profit Margin12.01%
Debt/Equity Ratio55.2%

How did 2633 perform over the long term?

See historical performance and comparison

Dividends

3.8%

Current Dividend Yield

25%

Payout Ratio

Valuation

Is Jacobson Pharma undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 2633 (HK$0.6) is trading below our estimate of fair value (HK$3.25)

Significantly Below Fair Value: 2633 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 2633 is good value based on its PE Ratio (6.6x) compared to the Hong Kong Pharmaceuticals industry average (9.9x).

PE vs Market: 2633 is good value based on its PE Ratio (6.6x) compared to the Hong Kong market (9.6x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 2633's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 2633 is good value based on its PB Ratio (0.5x) compared to the HK Pharmaceuticals industry average (1x).


Future Growth

How is Jacobson Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Jacobson Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Jacobson Pharma performed over the past 5 years?

6.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 2633 has a large one-off gain of HK$91.4M impacting its March 31 2021 financial results.

Growing Profit Margin: 2633's current net profit margins (12%) are lower than last year (13.6%).


Past Earnings Growth Analysis

Earnings Trend: 2633's earnings have grown by 6.1% per year over the past 5 years.

Accelerating Growth: 2633's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 2633 had negative earnings growth (-18.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (23.8%).


Return on Equity

High ROE: 2633's Return on Equity (6.5%) is considered low.


Financial Health

How is Jacobson Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: 2633's short term assets (HK$1.2B) exceed its short term liabilities (HK$873.9M).

Long Term Liabilities: 2633's short term assets (HK$1.2B) exceed its long term liabilities (HK$1.1B).


Debt to Equity History and Analysis

Debt Level: 2633's debt to equity ratio (55.2%) is considered high.

Reducing Debt: 2633's debt to equity ratio has increased from 49.5% to 55.2% over the past 5 years.

Debt Coverage: 2633's debt is well covered by operating cash flow (25.9%).

Interest Coverage: 2633's interest payments on its debt are well covered by EBIT (5.9x coverage).


Balance Sheet


Dividend

What is Jacobson Pharma current dividend yield, its reliability and sustainability?

3.83%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 2633's dividend (3.83%) is higher than the bottom 25% of dividend payers in the Hong Kong market (2.29%).

High Dividend: 2633's dividend (3.83%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.81%).


Stability and Growth of Payments

Stable Dividend: 2633 has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: 2633's dividend payments have increased, but the company has only paid a dividend for 5 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (25.4%), 2633's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.5yrs

Average board tenure


CEO

Derek Sum (58 yo)

no data

Tenure

HK$4,962,000

Compensation

Mr. Kwong Yip Sum, also known as Derek, is Non-Executive Chairman of the Board at JBM (Healthcare) Limited since September 22, 2020. He joined the company and its subsidiaries September 22, 2020. With exte...


CEO Compensation Analysis

Compensation vs Market: Derek's total compensation ($USD637.93K) is above average for companies of similar size in the Hong Kong market ($USD230.70K).

Compensation vs Earnings: Derek's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: 2633's board of directors are considered experienced (5.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Jacobson Pharma Corporation Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Jacobson Pharma Corporation Limited
  • Ticker: 2633
  • Exchange: SEHK
  • Founded: 2016
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$1.149b
  • Shares outstanding: 1.92b
  • Website: https://www.jacobsonpharma.com

Number of Employees


Location

  • Jacobson Pharma Corporation Limited
  • Tower 1, Millennium City
  • 23rd Floor
  • Kwun Tong
  • Kowloon
  • Hong Kong

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/15 15:52
End of Day Share Price2021/10/15 00:00
Earnings2021/03/31
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.